In liver, lipid nanoparticles (LNPs) were first used to deliver patisiran, currently the only siRNA drug on the market that uses this technology platform. The animal POC studies of LNP-mediated siRNA ...
Small interfering RNAs (siRNAs) offer significant therapeutic potential; however, extrahepatic applications, particularly to the skin, remain a challenge. Limited work has explored siRNA therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results